COMPARISONS and other Trials
|
|
TRANSFORMS |
|
SENTINEL |
|
CARE MS II |
|
|
|
IFN-1a IM |
Fingolimod |
IFN-1a IM |
NLZMAB+IFN |
INF-1a S/C |
ALM |
|
ARR |
0.33 |
0.16 |
0.75 |
0.34 |
0.52 |
0.26 |
|
ARR Red% |
|
52 |
|
55 |
|
49 |
|
Absolute Red % |
|
17 |
|
41 |
|
26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FREEDOMS |
|
AFFIRM |
|
|
|
|
Placebo |
Fingolimod |
Placebo |
NLZMAB |
|
|
ARR |
0.4 |
0.18 |
0.73 |
0.23 |
|
|
ARR Red% |
|
55 |
|
68 |
|
|
Absolute Red % |
|
22 |
|
50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Relative effectiveness (reduction in ARR – vs Ofatumumab)
Industry supported paper From Samjoo et al,. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020 Dec;9(18):1255-1274. doi: 10.2217/cer-2020-0122. Epub 2020 Oct 22. PMID: 33090003.
Time to Confirmed Disability progression at 6 months:
From JOCN 2014 (Broadley):
Rebif vs Copaxone
REGARD Trial (Lancet Neurology 2008)
Followed for ~2 years – no significant difference in safety or efficacy
Fingolimod vs Avonex
TRANSFORMS – NEJM 2010 362:402
• Fingolimod 1.25mg vs 0.5mg vs Interferon beta 1a (avonex) 30mcg
• Primary end point – Annual relapse rate
o 0.2 vs 0.16 vs 0.33
• New T2 lesions
o Significantly reduced
• Progression of sustained (>3months) disability
o Hardly any patients had progression of disability – no difference b/n any groups
Dimethyl Fumarate Vs Copaxone
• CONFIRM study
o ARRR BG12 vs Glaterimer - 44% vs 29%
BEYOND
• Lancet neurology Oct 2009
• Compared 3 groups - IFN 250ug, IFN 500ug and Glatiramer 20mg – all every second day
• No difference in efficacy between 3 groups
• Similar number had SE but different SE
• Ghjghj
o Ghjghj
• Ghjghjg